AU2001249064A1 - N-cadherin modulated migration, invasion, and metastasis - Google Patents

N-cadherin modulated migration, invasion, and metastasis

Info

Publication number
AU2001249064A1
AU2001249064A1 AU2001249064A AU4906401A AU2001249064A1 AU 2001249064 A1 AU2001249064 A1 AU 2001249064A1 AU 2001249064 A AU2001249064 A AU 2001249064A AU 4906401 A AU4906401 A AU 4906401A AU 2001249064 A1 AU2001249064 A1 AU 2001249064A1
Authority
AU
Australia
Prior art keywords
cadherin
metastasis
invasion
migration
modulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249064A
Inventor
Stuart Aaronson
Rachel B. Hazan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of AU2001249064A1 publication Critical patent/AU2001249064A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
AU2001249064A 2000-02-22 2001-02-22 N-cadherin modulated migration, invasion, and metastasis Abandoned AU2001249064A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18385200P 2000-02-22 2000-02-22
US60183852 2000-02-22
PCT/US2001/005645 WO2001062206A2 (en) 2000-02-22 2001-02-22 N-cadherin modulated migration, invasion, and metastasis

Publications (1)

Publication Number Publication Date
AU2001249064A1 true AU2001249064A1 (en) 2001-09-03

Family

ID=22674563

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249064A Abandoned AU2001249064A1 (en) 2000-02-22 2001-02-22 N-cadherin modulated migration, invasion, and metastasis

Country Status (3)

Country Link
US (1) US20030054985A1 (en)
AU (1) AU2001249064A1 (en)
WO (1) WO2001062206A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60237917D1 (en) * 2001-06-05 2010-11-18 Exelixis Inc GFATS AS MODULATORS OF THE P53 PATH AND METHOD OF USE
US7094754B2 (en) 2001-08-16 2006-08-22 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7186693B2 (en) 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
US7071164B2 (en) 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
US6906036B2 (en) 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
AU2003219679B2 (en) * 2002-01-23 2009-02-26 Texas Tech University Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells
US7148194B2 (en) 2002-12-30 2006-12-12 Kimberly-Clark Worldwide, Inc. Method to increase fibronectin
US7189700B2 (en) 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds
WO2007056604A2 (en) * 2005-11-09 2007-05-18 Irm Llc Methods and compositions for modulating cell motility and inhibiting tumor metastasis
AU2007227195A1 (en) * 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadherin and Ly6 E: targets for cancer diagnosis and therapy
US8663635B2 (en) * 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
AU2009231570A1 (en) 2008-04-04 2009-10-08 The Regents Of The University Of California Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
US9207242B2 (en) 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
US8703920B2 (en) 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin
WO2011094759A2 (en) * 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
EP2536414B1 (en) 2010-02-18 2016-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for preventing cancer metastasis
ES2690829T3 (en) 2012-09-17 2018-11-22 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for the selection of patients who respond to treatment
EA029531B1 (en) 2012-11-21 2018-04-30 Аджиос Фармасьютикалз, Инк. Glutaminase inhibiting compounds and pharmaceutical compositions comprising these compounds and use thereof
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
MX2016012244A (en) 2014-03-21 2017-05-08 Agios Pharmaceuticals Inc Compounds and their methods of use.
US10613088B2 (en) 2016-06-12 2020-04-07 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
US10761081B2 (en) 2016-06-12 2020-09-01 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
CN112384806A (en) * 2018-08-03 2021-02-19 西托根有限公司 Composition for diagnosing bone metastasis of cancer and kit comprising same
US20210263038A1 (en) * 2018-08-03 2021-08-26 Cytogen, Inc. Composition for diagnosis of bone metastasis of cancer and kit comprising same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06505962A (en) * 1990-10-30 1994-07-07 ラ　ホヤ　キャンサー　リサーチ　ファウンデーション T-cadherin adhesion molecule
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
US6169071B1 (en) * 1996-07-12 2001-01-02 Mcgill University Compounds and methods for modulating cell adhesion
US6562786B1 (en) * 1996-07-12 2003-05-13 Mcgill University Compounds and methods for modulating apoptosis
US5895748A (en) * 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
US6203788B1 (en) * 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6277824B1 (en) * 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function

Also Published As

Publication number Publication date
US20030054985A1 (en) 2003-03-20
WO2001062206A3 (en) 2001-12-20
WO2001062206A2 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
AU2001249064A1 (en) N-cadherin modulated migration, invasion, and metastasis
AU2001266513A1 (en) Parental control
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2001271744A1 (en) Leucine-rich repeat proteins, zlrr7, zlrr8 and zlrr9
AU2001232213A1 (en) Biometrics interface
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
AU4217299A (en) Pth1r and pth3r receptors, methods and uses thereof
AU3955701A (en) Communication control device and control method
AU4825099A (en) Wireless phone-line interface
AU3716501A (en) Wireless telephony interface and method
AU2001243394A1 (en) Compounds and methods
AU2088801A (en) Metastasis genes and uses thereof
AU2001285748A1 (en) Integrin ligands
AU2001292710A1 (en) Well packer and method
AU2001276399A1 (en) Communication control method and device
AUPQ872300A0 (en) Compounds and methods
AU2001290641A1 (en) Substituted fused pyrroleimines and pyrazoleimines
AU2002230506A1 (en) Proactive maintenance application
AU2001278951A1 (en) Compounds and methods
GB0103289D0 (en) Control and communication methods
AU2002364612A1 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
AU6102199A (en) Graphical user interface
AU2002235277A1 (en) Compounds and methods
AU2001244863A1 (en) Apoptin-associating protein